Session » RA – Diagnosis, Manifestations, and Outcomes Poster III

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1414

2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1416

Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study

1:00PM-3:00PM: Abstract Number: 1395

Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1392

Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic

1:00PM-3:00PM: Abstract Number: 1412

Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT

1:00PM-3:00PM: Abstract Number: 1415

Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study

1:00PM-3:00PM: Abstract Number: 1390

Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort

1:00PM-3:00PM: Abstract Number: 1413

Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study

1:00PM-3:00PM: Abstract Number: 1403

Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study

1:00PM-3:00PM: Abstract Number: 1394

Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort

1:00PM-3:00PM: Abstract Number: 1409

Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study

1:00PM-3:00PM: Abstract Number: 1405

In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker

1:00PM-3:00PM: Abstract Number: 1408

In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study

1:00PM-3:00PM: Abstract Number: 1391

Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1399

Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1406

Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1402

Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry

1:00PM-3:00PM: Abstract Number: 1407

Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study

1:00PM-3:00PM: Abstract Number: 1393

Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study

1:00PM-3:00PM: Abstract Number: 1400

Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1404

Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data

1:00PM-3:00PM: Abstract Number: 1398

Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1411

Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy

1:00PM-3:00PM: Abstract Number: 1387

Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe

1:00PM-3:00PM: Abstract Number: 1401

Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

1:00PM-3:00PM: Abstract Number: 1396

Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database

1:00PM-3:00PM: Abstract Number: 1410

Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital

1:00PM-3:00PM: Abstract Number: 1397

The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1389

The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors

1:00PM-3:00PM: Abstract Number: 1388

Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].